How should I manage a patient taking torsemide and Entresto (sacubitril/valsartan) who has a serum potassium of 3.4 mmol/L?

Management of Hypokalemia in a Patient on Torsemide and Entresto

You should supplement potassium to achieve a serum level ≥3.5 mmol/L before considering any diuretic dose escalation, as potassium of 3.4 mmol/L represents mild hypokalemia that requires correction but does not mandate discontinuation of either medication. 1

Immediate Assessment and Safety Thresholds

Your patient's potassium of 3.4 mmol/L falls below the severe hypokalemia threshold (<3.0 mmol/L) that would absolutely contraindicate diuretic dose increases, but still requires active management 1. The FDA labeling for Entresto specifically warns about hyperkalemia risk through RAAS inhibition, but your patient demonstrates the opposite problem—likely driven by loop diuretic effects 2.

Key clinical parameters to evaluate:

• Blood pressure must be ≥90-100 mmHg to safely continue current therapy 1
• Assess for signs of volume overload (weight gain >1.4 kg, peripheral edema, elevated JVP, pulmonary crackles) to determine if diuretic adjustment is needed 1
• Check renal function: serum creatinine should be <2.5 mg/dL or eGFR >30 mL/min/1.73 m² for safe continuation 1

Potassium Repletion Strategy

Initiate oral potassium supplementation immediately to restore serum potassium to ≥3.5 mmol/L, which is the target range for patients on RAAS inhibitors 1. The combination of torsemide (a loop diuretic causing potassium loss) and Entresto (which typically increases potassium through RAAS inhibition) creates a unique situation where the diuretic effect is dominating 2, 3.

Loop diuretics like torsemide promote potassium excretion, though torsemide has some aldosterone-blocking properties that make it relatively more potassium-sparing than furosemide 4, 5. However, this protective effect is clearly insufficient in your patient.

Diuretic Management Considerations

Do not increase the torsemide dose until potassium is corrected 1. If the patient has evidence of congestion requiring more aggressive diuresis:

• First optimize potassium levels
• Ensure strict sodium restriction to ≤2 g daily to enhance diuretic response 1
• Consider fluid restriction to 2 liters daily if edema persists 1
• Only after potassium normalization, if diuretic resistance occurs, consider adding metolazone 2.5-10 mg daily for sequential nephron blockade—but this markedly increases electrolyte depletion risk and requires intensive monitoring 1

Entresto Continuation

Continue Entresto without dose adjustment unless symptomatic hypotension develops 2. The PARADIGM-HF trial demonstrated that sacubitril/valsartan actually reduces the risk of severe hyperkalemia compared to enalapril when combined with mineralocorticoid receptor antagonists (3.3 vs 2.3 per 100 patient-years; HR 1.43, p=0.003) 6. Your patient's hypokalemia suggests the diuretic effect is predominant, and Entresto may actually be providing some protective buffering against more severe potassium depletion.

Research shows that even very low doses of sacubitril/valsartan (half of 24/26 mg BID) significantly reduce NT-proBNP and diuretic requirements without changing potassium or creatinine 7. This suggests Entresto is not the primary driver of electrolyte disturbance in your patient.

Monitoring Protocol

Recheck electrolytes, renal function, and blood pressure within 1-2 weeks after initiating potassium supplementation or any medication adjustment 1, 8. The 2022 ACC/AHA/HFSA guidelines emphasize that diuretics should be used at the lowest dose possible to maintain euvolemia while always being combined with guideline-directed medical therapy like Entresto that reduces hospitalizations and prolongs survival 9.

Common Pitfalls to Avoid

• Do not discontinue Entresto due to mild hypokalemia—the mortality benefit of ARNI therapy in heart failure with reduced ejection fraction is substantial, and this potassium level does not represent a contraindication 9, 2
• Do not reflexively reduce torsemide if the patient has persistent volume overload, as untreated congestion worsens outcomes 1
• Do not add combination diuretic therapy (thiazides or metolazone) until potassium is corrected and single-agent loop diuretic optimization has been attempted 1